

## Decentralized Clinical Trials: Diversity in Clinical Trials

Article By:

Jessica M. Boubker

Monica R. Chmielewski

---

On March 15, 2024, the U.S. Food and Drug Administration (FDA) announced that it had approved the first decentralized clinical trial (DCT) for a new drug. This DCT, [Click here](#) to explore the series on decentralized clinical

trials, is a significant milestone in the history of clinical research. The DCT, known as the [Click here](#) trial, is a phase 1 trial for a new drug, and it is the first DCT to be approved by the FDA. The trial is a significant milestone in the history of clinical research, as it represents a shift from traditional centralized clinical trials to decentralized clinical trials. The DCT is a significant milestone in the history of clinical research, as it represents a shift from traditional centralized clinical trials to decentralized clinical trials.

On October 2, 2024, the U.S. Food and Drug Administration (FDA) announced that it had approved the first decentralized clinical trial (DCT) for a new drug. This DCT, [Click here](#) to explore the series on decentralized clinical

trials, is a significant milestone in the history of clinical research. The DCT, known as the [Click here](#) trial, is a phase 1 trial for a new drug, and it is the first DCT to be approved by the FDA. The trial is a significant milestone in the history of clinical research, as it represents a shift from traditional centralized clinical trials to decentralized clinical trials. The DCT is a significant milestone in the history of clinical research, as it represents a shift from traditional centralized clinical trials to decentralized clinical trials.

On October 2, 2024, the U.S. Food and Drug Administration (FDA) announced that it had approved the first decentralized clinical trial (DCT) for a new drug. This DCT, [Click here](#) to explore the series on decentralized clinical

~~DO NOT EDIT OR REFORMAT THIS DOCUMENT. ANY CHANGES WILL BE REVERSED.~~

We will continue to monitor FDA and other regulatory rule changes or guidance

*Daniel S. Costandy contributed to this article.*

© 2024 Foley & Lardner LLP

---

National Law Review, Volumess XIII, Number 340

Source URL: <https://natlawreview.com/article/decentralized-clinical-trials-diversity-clinical-trials>